Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia

Sharareh Siamakpour-Reihani, Felicia Cao, Jing Lyu, Yi Ren, Andrew B. Nixon, Jichun Xie, Amy T. Bush, Mark D. Starr, James R. Bain, Michael J. Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L. Huebner, Nelson J. Chao, Anthony D. Sung

Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, United States of America, Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, United States of America

Abstract

Although hematopoietic stem cell transplantation (HCT) is the only curative treatment for acute myeloid leukemia (AML), it is associated with significant treatment related morbidity and mortality. There is great need for predictive biomarkers associated with overall survival (OS) and clinical outcomes. We hypothesized that circulating metabolic, inflammatory, and immune molecules have potential as predictive biomarkers for AML patients who receive HCT treatment. This retrospective study was designed with an exploratory approach to comprehensively characterize immune, inflammatory, and metabolomic biomarkers. We identified patients with AML who underwent HCT and had existing baseline plasma samples. Using those samples (n = 34), we studied 65 blood based metabolomic and 61 immune/inflammatory related biomarkers, comparing patients with either long-term OS (≥3 years) or short-term OS (OS ≤1 years). We also compared the immune/inflammatory response and metabolomic biomarkers in younger vs. older AML patients (<30 years vs. ≥55 years old). In addition, the biomarker profiles were analyzed for their association with clinical outcomes, namely OS, chronic graft versus host disease (cGVHD), acute graft versus host disease (aGVHD), infection and relapse. Several baseline biomarkers were elevated in older versus younger patients, and baseline levels were lower for three markers (IL13, SAA, CRP) in patients with OS ≥3 years. We also identified immune/inflammatory response markers associated with aGVHD (IL-9, Eotaxin-3), cGVHD (Flt-1), infection (D-dimer), or relapse (IL-17D, bFGF, Eotaxin-3). Evaluation of metabolic markers demonstrated higher baseline levels of medium- and long-chain acylcarnitines (AC) in older patients, association with aGVHD (lactate, long-chain AC), and cGVHD (medium-chain AC). These differentially expressed profiles merit further evaluation as predictive biomarkers.
Introduction

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease with biological complexity [1]. There have been major advances in understanding the genetic factors related to AML and the disease biology and pathophysiology during the past thirty years. However, induction chemotherapy and consolidation therapy with allogeneic hematopoietic stem cell transplant (HCT) or additional chemotherapy remains the standard treatment, with about 20–30% of AML patients never achieving remission [2]. This is true specifically for intermediate- or high-risk AML patients who have increased risk of relapse, and HCT remains the best and only chance for cure. Yet, HCT is associated with severe treatment related morbidities such as infections and graft-versus-host disease (GVHD), and risk of non-relapse mortality ranges from 8–38% [3, 4]. Low rates of complete remission (CR) (30–50%) and poor overall survival (OS) (15–55% at one year) have been attributed to a variety of reasons including increased incidence of poor-risk cytogenetics, mutations such as FMS-like tyrosine kinase 3 with the internal tandem duplication (FLT3-ITD), increased activation of RAS, Src, and TNF pathways, and intrinsic resistance of leukemic blasts to therapeutic agents [5–7].

The incidence of AML increases with age, with the biology of AML changing with age [5]. Unfortunately, many older AML patients are considered unfit for intensive treatment because of frailty and the risk of fatal toxicity [1, 2, 8, 9]. Even in older patients who receive intensive treatment, outcomes remain unsatisfactory with low rates of CR, poor disease-free survival (DFS) and OS [3, 4]. Given improvements in therapeutic regimens and supportive care (including infection control and transfusion support), in patients younger than 60, AML is now cured in approximately 35–40% of cases. However, for AML patients >60 years, although the prognosis has improved, survival is still poor, with OS<1 year compared to OS of almost 3 years for patients aged 15 to 55 [5, 8–10].

Genomic profiles and multiple somatically-acquired mutations can be used for AML characterization, affecting prognosis and serving as predictive biomarkers. Genetic alterations in AML can be divided into three groups: 1) cytogenic abnormalities such as translocations, inversions, deletions, trisomies and monosomies, 2) cytogenetically normal but with gene mutations, such as in NPM1, FLT3, CEPBA, RAS, WT1, and TP53 and 3) epigenetic mutations, such as DNMT3A, IDH1/2, and TET (C). In AML patients, genetic screening is used for prognostic categorization (favorable, intermediate, and poor risk) and the subsequent selection of treatment strategies. Currently, the World Health Organization (WHO) classification of myeloid neoplasms distinguishes between AML with mutations in RUNX1 and AML with the BCR-ABL1 fusion. In addition, the 2017 European LeukemiaNet recommendations for AML adds mutations in three genes—RUNX1, ASXL1, and TP53—for risk stratification of AML [11, 12]. The random accumulation of mutations due to aging is one reason that AML is considered a disease of the elderly. Despite these genetic associations, there is a need for additional blood based markers for phenotyping patients because genetics alone are not fully prognostic.

Aging is a complex process that is characterized by physical, molecular, and deleterious immune and metabolic changes [13, 14]. Biological aging is characterized by dysregulated immune and metabolic homeostasis [15]. Regardless of the cause, a common feature of aging and many age-related diseases is chronic inflammation in the absence of infection (termed “inflammaging”). Changes in circulating levels of blood based biomarkers of inflammation/immune response have been shown to be associated with inflammaging. Examples of such biomarkers are C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and its soluble receptors (tumor necrosis factor receptors I (TNFR-I) and II (TNFR-II)), vascular cell adhesion molecule I (VCAM-I), and D-dimer [14, 16, 17]. The Pepper Panel, developed by the Duke Pepper Center for Aging, includes biomarkers of aging,
inflammation, mitochondrial dysfunction, and dysregulated protein metabolism. Age was positively correlated with TNF-α, TNFR-I, TNFR-II, IL-6, IL-2, VCAM-1, D-dimer, matrix metalloproteinase-3 (MMP-3) and adiponectin markers; age was negatively correlated with G-CSF, RANTES, and paraoxonase activity [14].

Metabolic changes are part of the aging process. Aging related dysregulation of inflammatory/immune responses occurs in tandem with metabolomic dysregulation. However, the mechanisms are poorly understood [14]. It has been reported that changes in such circulating, energy–related metabolites as acylcarnitines, carbohydrates, and amino acids (AA), can be associated with age, BMI and insulin resistance. Metabolic markers such as adiponectin, glycine, nonessential AA, and relative proportions of circulating large, neutral AAs (LNAAs) and medium–chain acylcarnitines have been suggested as markers of metabolic health. For example, higher plasma concentrations of glycine have been reported to be associated with better metabolic health [14, 18–20].

We hypothesized that circulating metabolic, inflammatory, and immune molecules have potential as predictive biomarkers for AML patients who receive HCT treatment. We have studied those biomarkers in AML-HCT patients who have shorter vs longer OS (OS of less than one year (OS ≤ 1) or more than three years (OS ≥ 3). We compared the blood based biomarkers and metabolomics profiles in younger vs. older AML patients (≤ 30 years vs. patients ≥ 55 years). We also analyzed the biomarker and metabolomics profiles for their association with clinical outcomes, namely OS, chronic graft versus host disease (cGVHD), acute graft versus host disease (aGVHD), infection and relapse.

Methods

Patient population

We retrospectively identified patients with AML who underwent HCT, and had baseline (pre-HCT) EDTA plasma samples. The samples were stored according to our Duke Health Institutional Review Board (IRB)-approved protocols (IRB# Pro00006268 and Pro00100650). Our protocols involved obtaining witnessed informed consent for sample collection for future research purposes, as well as use of associated clinical data.

Fully anonymized samples were thawed, aliquoted, refrozen and stored at −80˚C until tested. All samples underwent one freeze–thaw cycle before ELISA analysis. In order to compare biomarkers in older vs. younger patients and those with good vs. poor OS outcomes, we selected samples based on patient age (≤ 30 years vs. ≥ 55 years old) and OS outcomes (OS ≤ 1 years vs. OS ≥ 3 years). (Table 1). The age cut-offs were arbitrary selection and mostly based on what we had samples for. Though there is support that AML in patients >55years behaves differently than AML in patients <55 years [5].

Biomarkers of inflammation and aging

To evaluate plasma biomarkers of inflammation/immune response, we employed the Meso Scale Quickplex SQ 120 system from Meso Scale Diagnostic (MSD), LLC. (Rockville, MD). We used the V-PLEX Human Biomarker 54-Plex Multiplex Plates, (Cat#K15248D, MesoScale Diagnostics, Rockville, MD). The 54-Plex is designed to provide a multiplex assay for measuring markers involved in inflammation response and immune system regulation [21–23]. As previously mentioned the biological aging is characterized by dysregulated immune and metabolic homeostasis [15]. We chose the 54–plex to get a broad understanding of the potential differences in the immune/inflammatory response biomarker based on the patients’ age, survival and their association with clinical outcomes. The 54-Plex assay evaluated the following markers: CRP, eotaxin, eotaxin-3, FGF (basic), GM-CSF, ICAM-1, IFN-γ, IL-10, IL-12/IL-23p40,
IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17B, IL-17C, IL-17D, IL-1RA, IL-1α, IL-1β, IL-2, IL-21, IL-22, IL-23, IL-3, IL-31, IL-4, IL-5, IL-6, IL-7, IL-8 (HA), IL-9, IL-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, MIP-3α, PI GF, SAA, TARC, Tie-2, TNF-α, TNF-β, TSLP, VCAM-1, VEGF-A, VEGF-C, VEGF-D, and VEGFR-1/Flt-1. Each individual multiplex panel was run at the prespecified dilution for optimal performance and all samples were tested in duplicate.

To evaluate plasma biomarkers of aging, we also used markers from the Duke Pepper Panel [14], and other markers reported as significant in GVHD (REG3 and ST2) [24, 25]. The Duke Pepper Panel included the following 12 blood based markers: adiponectin, IL-2, IL-6, TNF-α, TNFR1, TNFRII, D-dimer, G-CSF, regulated on activation, normal T cell expressed and secreted (RANTES)*, MMP-3*, paraoxonase*, VCAM-1 [14]. Many of these biomarkers were
already included in the 54-Plex panel, markers denoted by * were analyzed using separate enzyme-linked immunosorbent assay (ELISAs) including: RANTES (MesoScaleDiscovery Cat#F21ZN-3), TNFRI/TNFRII/MMP-3 (MesoScaleDiscovery Cat#F210V-3/F21ZS-3) D-dimer (Sekisui Diagnostics Cat#602), IL6Ra (R&D Systems Cat#DR600), and Paraoxonase (Invitrogen Molecular Probes Cat#E33702).

To evaluate plasma biomarkers of GVHD, in addition to IL6R as described above, samples were analyzed using ELISAs for regenerating family member 3 alpha (REG3A) (MBL Cat#5323/5310) [26–28]: REG3A is an anti-microbial peptides (AMP) and has been identified and validated as a diagnostic biomarker of gastrointestinal (GI) GVHD [24, 29]. Plasma REG3A plasma concentrations have been reported to be higher in GI GVHD patients [24, 30]. We have also evaluated suppression of tumorigenicity 2 (ST2, also known as interleukin 1 receptor like 1, (IL1RL1), IL1RL1/ST2 MesoScaleDiscovery Cat#F214H-3). ST2 has been evaluated as biomarker of GVHD, with elevated ST2 levels being associated with therapy-resistant GVHD and mortality [25, 30].

Biomarkers of metabolism

We evaluated 65 metabolic biomarkers including: amino acids (N = 15), acylcarnitines (N = 45), and conventional clinical analytes (N = 5). Amino acids and acylcarnitines were analyzed by flow injection electrospray-ionization tandem mass spectrometry and quantified by isotope or pseudo-isotope dilution using methods described previously [31, 32]. Conventional analytes, including non-esterified fatty acids (NEFA), triglycerides, glycerol, 3-hydroxybutyrate, and lactate and were measured using a Beckman DxC 600 clinical analyzer (Brea, CA). Reagents for 3-hydroxybutyrate and NEFA were from Wako (Mountain View, CA), and those for lactate and triglycerides were from Beckman (Brea, CA). We measured free glycerol using the initial absorbance in the triglycerides assay, a signal that is normally blanked in the test procedure preceding the addition of lipase.

Statistical analysis for biomarker studies

The 54-plex immune/inflammatory response biomarkers, the additional plasma biomarkers, and metabolomic biomarkers were analyzed using Cox Proportional Hazard models with OS as the response, and age groups, baseline biomarkers, and their interactions as predictors. Corresponding to the Cox PH model, p-values were reported from Chi-square test with df = 2 [33]. Box plots were used to illustrate the variability of the markers for association with clinical outcomes. Boxes represent 25th (Q1) and 75th (Q3) percentiles; Horizontal lines indicate the medians; Upper whiskers indicate maximum; Lower whiskers indicate minimum; Points indicate any observations outside the whiskers. Expression levels were log2-transformed and analyzed as continuous measures (Please see S1 File for the data underlying the findings). OS groups with survival of equal and less than one year or more than three years (OS \(\leq\) 1 years or OS \(\geq\) 3 years) were used as the output in logistic regression models. OS time was defined as time from transplant to death/last follow-up. Baseline samples’ biomarker levels in different age and OS groups were analyzed using a Wilcoxon rank-sum test [34]. Effect sizes of each biomarker for aGVHD, cGVHD, relapse and infection were assessed using logistic regression models. Odds ratios (OR), score test p-values, and 95% CI were reported for the logistic regression models assessing biomarker effects on clinical outcomes (aGVHD, cGVHD, relapse and infection). Multiple comparison was addressed within a framework of control of False Discovery Rate (FDR) using the method by Storey [35, 36]. However, due to the limited sample size and number of markers analyzed, we used 0.1 as the significant q-value cutoff.
All analyses were performed using the R Statistical Environment [R], [6] and extension packages from CRAN [37, 38]. The analyses were conducted with adherence to the principles of reproducible analysis using the knitr package for generation of dynamic reports [39].

**Results**

### Blood based biomarkers

Evaluation of the blood based immune/inflammatory response markers in younger vs. older HCT patients revealed significant differences in the pre-HCT baseline levels of the biomarkers (Table 2 and Fig 1). Compared to younger patients, older patients tended to have higher values of the following markers (Fig 1A–1H): interleukin-6 (IL6 p-value = 0.002), interleukin-12 (IL12/IL12p70 p-value = 0.031), interleukin-16 (IL16 p-value = 0.022), interleukin-17 (IL17B p-value = 0.028, IL17C p-value = 0.007, IL17D p-value = 0.032, IL17A p-value = 0.036), interleukin-27 (IL27 p-value = 0.008), interleukin-1 receptor antagonist (IL1RA p-value = 0.015), macrophage inflammatory protein (MIP1α p-value = 0.041), placental growth factor (PIGF p-value = 0.001), thymic stromal lymphopoietin (TSLP, p-value = 1.0×10^-4), tumor necrosis factor alpha (TNF-α (also known as TNF) p value = 0.010), cell receptors tumor necrosis factor receptor I (TNFRI, p-value = 0.013) and tumor necrosis factor receptor II (TNFRII, p-value = 0.005), cellular adhesion protein vascular cell adhesion molecule 1 (VCAM1 p-value = 0.0002), and apolipoprotein serum amyloid A (SAA, p-value = 0.019) (Table 2). This higher baseline inflammatory state may predispose older patients to worse outcomes after HCT, including the potential for increased risk of GVHD [40, 41]. Our data demonstrates that only interleukin-23 (IL23α, p-value = 0.022) was significantly higher in younger patients (age ≤ 30 years) compared to older patients (age ≥ 55 years) (Fig 1).

| Marker Base level | p value |
|-------------------|---------|
| TSLP              | 0.00009 |
| VCAM1             | 0.0002  |
| PIGF              | 0.001   |
| IL6               | 0.002   |
| IL17C             | 0.007   |
| IL27              | 0.008   |
| TNFRI*            | 0.005   |
| TNF-α             | 0.010   |
| TNFRI*            | 0.013   |
| IL1RA             | 0.015   |
| SAA               | 0.019   |
| IL23 **           | 0.022   |
| IL16              | 0.022   |
| IL17B             | 0.028   |
| IL12p70           | 0.031   |
| IL17D             | 0.032   |
| IL17A             | 0.036   |
| MIP1α             | 0.041   |

* are separate ELISAs not part of the 54-plex.
** Higher baseline levels in younger patients.

https://doi.org/10.1371/journal.pone.0268963.t002
Association between OS and baseline biomarker expression. Evaluating the association between OS and baseline biomarker expression using the Wilcoxon Rank-Sum test revealed that three markers C-reactive protein (CRP, p-value = 0.027), SAA (p-value = 0.018) and IL13, p-value = 0.017) had significant association with survival regardless of age. Baseline levels are lower in all the three markers in patients with OS < 3 years (Fig 2).

Association between baseline biomarker levels and clinical outcomes (aGVHD, cGVHD, relapse and infection). Baseline levels of three biomarkers were significantly associated with post-HCT “relapse”. Patients with post HCT relapse had lower baseline levels of Interleukin 17D (IL17D, OR = 0.17, 95% CI = (0.03, 0.63), p-value = 0.020) and fibroblast growth factor 2 (bFGF (also known as FGF2), OR = 0.63, 95% CI = (0.38, 0.94), p-value = 0.038). In contrast, patients with relapse had higher baseline levels of eotaxin-3 (OR = 3.89, 95% CI = (1.43, 15.64), p-value = 0.027) (Fig 3A–3C). Only D-dimer was significantly associated with infection post-HCT; patients who developed infection post-HCT had higher baseline levels of D-dimer (OR = 2.68, 95% CI = (1.18, 7.91), p-value = 0.038) (Fig 3D).

One baseline plasma marker was significantly associated with cGVHD: fms-like tyrosine kinase 1 (Flt-1, also known as VEGFR-1, OR = 1.71, 95% CI (1.13, 2.78), p-value = 0.017). Patients who developed cGVHD post-HCT had higher baseline expression levels of Flt-1 (Fig 3E).
Two baseline plasma markers were significantly associated with aGVHD: interleukin 9 (IL-9, OR = 0.37, 95% CI (0.16, 0.71), p-value = 0.009); and eotaxin-3 (also known as C-C motif chemokine ligand 26 (CCL26), OR = 0.35, 95% CI = (0.11, 0.84), p-value = 0.040). Patients who developed aGVHD post-HCT had lower baseline expression levels of both markers (Fig 3F and 3G).

**Metabolic biomarkers**

The aging process is a complex, characterized by physical, molecular, immune, and metabolic changes that can cause functional decline [24, 28]. In addition to evaluating plasma biomarkers of immune and inflammatory response, we have 65 metabolites, including: amino acids (N = 15), acylcarnitines (N = 45), and conventional clinical analytes (N = 5). Markers were evaluated for association with age, OS and clinical outcomes (aGVHD, cGVHD, relapse and infection).

Association between baseline metabolic biomarkers and clinical outcomes (aGVHD, cGVHD, relapse and infection). No metabolic marker showed significant association with survival for AML/HCT patients.

Baseline circulating lactate was associated with development of aGVHD post HCT. Patients with aGVHD had lower baseline levels of lactate (LACT, OR = 0.24, 95% CI = (0.06, 0.69), p-value = 0.019) (Fig 3H). Baseline acylcarnitines (AC) also demonstrated association with aGVHD, specifically C2-acylcarnitine, 3-hydroxy-tetradecanoyl carnitine or dodecanediol carnitine (C14-OH/C12-DC, OR = 0.24, 95% CI = (0.05,0.75), p-value = 0.028), 3-hydroxy-tetradecenoyl carnitine (C14:1-OH, OR = 0.35, 95% CI = (0.11, 0.93), p-value = 0.049), and long-chain acylcarnitines. Patients with aGVHD had lower baseline levels of C14-OHC12-DC and C14:1-OH compared to patients with no aGVHD. Baseline levels of a medium-chain AC markers of oxidative stress, glutaryl carnitine, (C5-DC), demonstrated association with cGVHD. In contrast to aGVHD, patients with cGVHD had higher levels of C5-DC (OR = 4.97, 95% CI = (1.49, 21.99), p-value = 0.017). (Fig 3I–3K).

Compared to younger patients, baseline levels of various medium- and long-chain acylcarnitines [42] (p<0.05) were higher in older HCT patients. (Fig 4 and metabolomics S2 File).
**Discussion**

Age related inflammation, also termed “inflammaging” is related to the activation/dysregulation of both innate and adaptive immune systems and is considered a significant risk factor in many age-related diseases [13, 16]. The exact mechanism of inflammaging and its contribution to adverse health outcomes are mostly unknown [16]. However, numerous studies have shown that several pro inflammatory cytokines, including IL-6 and TNF-α, increase with age in healthy individuals and in the absence of infection [43–45].

Of the 61 immune and inflammatory response related biomarkers we investigated, 17 were increased in older patients and only one marker (IL-23) was increased in younger patients pre-HCT compared to older patients. Unsurprisingly, most of the biomarkers elevated in elderly patients were inflammatory cytokines, such as IL16, IL17, MIP1a, TNF-α, and TNF receptors TNFRI and TNFRII. In addition, TNF-α is an essential signaling protein in the innate and adaptive immune systems, is considered a biomarker of HCT treatment toxicity and a key cytokine in the effector phase of GVHD. TNF inhibitors have shown efficacy in clinical and experimental models of GVHD [46, 47]. Surprisingly, IL-23 levels were increased in younger patients compared to older patients. The differing expression levels of IL-23 and IL-17 were unexpected, since IL-23 and IL-17 are closely intertwined. IL-23 is known to drive promotion...
of T helper type 17 (Th17) cells that secrete IL-17 [48]. This signaling pathway is critical in autoimmune conditions such as psoriasis and rheumatoid arthritis, and therapeutics targeting IL-17 or IL-23 are under clinical investigation [49]. In addition, ustekinumab, an antibody targeting IL-23 was reported to be effective in glucocorticoid-refractory aGVHD [50]. Other potential targets for aGVHD treatment involving the IL-23/IL-17 pathway, include the bromo-domain and extra-terminal domain (BET) proteins.

In vitro and in vivo assays [51], have demonstrated the potent anti-inflammatory effects of BET inhibition, and its effect on impacting IL-23R/IL-17 immune axis (decreasing the expression levels of IL23-R and IL17). BET inhibitors (Plexxikon-51107 and -2853 (PLX51107 and PLX2853)) have demonstrated that they can significantly improves survival and reduces aGVHD progression. PLX51107 will be studied in a phase Ib/II clinical trial for its effects on treating Steroid-Refractory aGVHD (NCT04910152) [51].

Baseline levels of three markers (CRP, SAA and IL13) showed significant association with survival. Basal levels were lower in all the three markers in HCT patients with longer OS (OS ≥ 3 years). IL-13 is involved in Th2 inflammation and higher pre transplant levels of IL13 have been reported as a strong predictor of developing aGVHD [52]. IL13 and its receptors have been evaluated as a possible therapeutic target in different diseases including various types of cancer [52–55].
Clinically, CRP is frequently examined broad-scale in a variety of disease states. CRP, C-reactive protein, is often measured as a broad-scale marker of inflammation in infection and autoimmune/rheumatologic conditions [56]. SAA or serum-amyloid A is a group of apolipoproteins associated with high density lipoprotein (HDL) that is both expressed constitutively and in response to inflammation [57]. Additionally, SAA has been implicated in the suppressive effects of tumor cells on immune cells in both melanoma and glioblastoma models [58, 59].

Similar to CRP, D-dimer is an established biomarker of a number of disease states. D-dimer, a product of blood clot degradation, is most often measured when there is suspicion of pulmonary embolism or deep-vein thrombosis, but it can also be elevated in infection, inflammation, pregnancy, trauma, and malignancy [60]. The association between elevated D-dimer and infection post-HCT observed here might suggest a chronic inflammatory state, which combined with the immnosuppression after bone marrow transplant might lead to increased inability to fight off infection. CRP, D-dimer and SAA are notable for being highly upregulated during the “acute phase response”–the body’s physiological reaction to stresses such as infection, inflammation, and trauma [61].

Of the 65 metabolomic biomarkers analyzed, we noted that lower mean levels of lactate were associated with aGVHD. A growing body of clinical evidence indicts dysregulation of lactate–pyruvate fuel metabolism in poor clinical outcomes after HCT [62, 63]. Lactate is the product of glycolysis and substrate for mitochondrial respiration. It has a variety of roles, including its importance as an energy source, a precursor for gluconeogenesis, and an essential signaling molecule [64]. Critically, T cells rely upon glycolysis and lactate to perform their effector functions. In fact, 13C-pyruvate MRI has been used to detect aGVHD in a mouse model of HCT. In that study, plasma levels of lactate were significantly elevated at day 7 post-HCT after allogenic but not syngeneic transplants [65]. This timing of lactate elevation could explain why we observed that a lower baseline level of lactate was associated with aGVHD.

Acylcarnitines also play an important role in energy metabolism by participating in the transfer of fatty acids into mitochondrial membrane [42, 66]. Acylcarnitines, esters of L-carnitines and fatty acids, are important intermediates in metabolism. They are responsible for transporting long chain fatty acids across the mitochondria for beta-oxidation. They have been used as biomarkers for inherited metabolic disorders since dysfunction in fatty acid or amino acid metabolism can lead to changes in plasma acylcarnitine concentration [67]. Our previous studies have shown that long-chain acylcarnitines, and carnitine esters of dicarboxylic acids are associated with cardiovascular disease, including heart failure [68–70]. Acylcarnitines can mediate inflammation [71], and have been proposed as biomarkers for hepatocellular carcinoma and liver dysfunction since the liver is the most active organ for acylcarnitine synthesis and metabolism [72].

Our results suggest that baseline levels of medium- and long-chain AC markers were higher in older HCT patients compared to younger HCT patients. In patients with aGVHD compared to patients who did not develop aGVHD, the baseline levels of certain long-chain acylcarnitines were lower. Baseline levels of the short chain AC marker, glutaryl carnitine, C5- DC [42], a marker of omega oxidation and oxidative stress, demonstrated association with cGVHD: patients with cGVHD had higher levels of C5-DC. Accumulation of medium- and long-chain acylcarnitines in older patients suggests incomplete beta-oxidation of fatty acids, resulting in lower flux of fatty hydrocarbon toward acetylcarminine (AC C2) and, hence, acetyl CoA. To maintain overall energy balance, glycolytic pyruvate metabolism might shift away from lactic acid and toward production of acetyl CoA and Krebs cycling [73, 74].

Our data show a significant decrease in lactate with aGVHD, as they also do decreases in various ACs. This could potentially signify a pathway emphasis towards Krebs (and oxidative phosphorylation) and away from lactate or fatty acid synthesis, or alternatively a drive in the
opposite direction through pyruvate towards gluconeogenesis. In order to have the data and conclusion, to support such claims further in-depth studies are needed. Strengths of this exploratory study include the large number of biomarkers (>100 total) analyzed from patient samples, the long-term survival data, and similar pre-HCT and peri-HCT conditioning treatment. The major limitation of this study is the small cohort size. The small sample size and the large number of the markers will not allow for the adjusted p-value analysis. Other limitations include disparate cohort sizes, lack of matched healthy control data and reliance on single institution data. In addition, we have only measured the baseline levels of the markers, which did not evaluate the longitudinal changes of these markers (including known GVHD markers REG3 and ST2, that did not show significant association in our baseline analysis). As previously stated this retrospective study was designed with an exploratory and hypothesis-generating approach to comprehensively characterize immune, inflammatory, and metabolomic biomarkers. Thus, biomarkers highlighted here should be subjected to further analyses.

In conclusion, we have identified several inflammatory and metabolomic biomarkers that are differentiate young vs old HCT patients and are associated with survival and clinical outcomes in HCT. Many of these biomarkers have been previously associated with malignancy or immune responses. Given the generally poor outcomes for older patients with AML, additional investigation is warranted. A combination of biomarkers could guide interventions, and personalized immune-modulatory therapeutics post-HCT could help to improve clinical outcomes in AML.

Supporting information
S1 File. (ZIP)
S2 File. (PDF)

Acknowledgments
We a like to thank Huaxia Cui and Tabitha George for their assistance in with metabolomics assay measurements.

Author Contributions
Conceptualization: Sharareh Siamakpour-Reihani, Anthony D. Sung.
Data curation: Felicia Cao.
Formal analysis: Jing Lyu, Yi Ren, Jichun Xie, Mark D. Starr.
Funding acquisition: Anthony D. Sung.
Investigation: Sharareh Siamakpour-Reihani, Nelson J. Chao, Anthony D. Sung.
Methodology: Sharareh Siamakpour-Reihani, Andrew B. Nixon, Amy T. Bush, Mark D. Starr, James R. Bain, Michael J. Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L. Huebner, Anthony D. Sung.
Project administration: Sharareh Siamakpour-Reihani.
Resources: Amy T. Bush, Nelson J. Chao, Anthony D. Sung.
Supervision: Sharareh Siamakpour-Reihani, Andrew B. Nixon, Jichun Xie, James R. Bain, Virginia Byers Kraus, Anthony D. Sung.

Writing – original draft: Sharareh Siamakpour-Reihani, Felicia Cao.

Writing – review & editing: Sharareh Siamakpour-Reihani, Felicia Cao, Jing Lyu, Yi Ren, Andrew B. Nixon, Jichun Xie, Amy T. Bush, Michael J. Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L. Huebner, Nelson J. Chao, Anthony D. Sung.

References

1. Medinger M, Heim D, Halter JP, Lengerke C, Passweg JR. [Diagnosis and Therapy of Acute Myeloid Leukemia]. Therapeutische Umschau Revue therapeutique. 2019; 76(9):481–6. https://doi.org/10.1024/0040-5930/a001126 PMID: 32157963

2. Medinger M, Lengerke C, Passweg J. Novel therapeutic options in Acute Myeloid Leukemia. Leukemia Research Reports. 2016; 6(Supplement C):39–49.

3. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(11):1878–87. https://doi.org/10.1200/JCO.2009.25.4821 PMID: 2012255

4. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(15):3439–46. https://doi.org/10.1200/JCO.2005.05.694 PMID: 15824415

5. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006; 107(9):3481–5. https://doi.org/10.1182/blood-2005-09-3724 PMID: 16455952

6. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009; 145(5):598–605. https://doi.org/10.1111/j.1365-2141.2009.07663.x PMID: 19344426

7. Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351–61. https://doi.org/10.1002/cncr.23697 PMID: 18618511

8. Juliusson G, Antunovic P, Deroif Å, Lehmann S, Möllgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113(8):4179–87. https://doi.org/10.1182/blood-2008-07-172007 PMID: 19008455

9. Estey E. Acute myeloid leukemia: 2016 Update on risk-stratification and management. Am J Hematol. 2016; 91(8):824–46. https://doi.org/10.1002/ajh.24433 PMID: 27417880

10. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2015; 29(1):51–7. https://doi.org/10.1038/leu.2014.164 PMID: 24913728

11. Bullinger L, Döhner K, Döhner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2017; 35(9):934–46.

12. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New England Journal of Medicine. 2015; 373(12):1136–52. https://doi.org/10.1056/NEJMra1406184 PMID: 26376137

13. Ariffin H, Azanan MS, Abd Ghafar SS, Oh L, Lau KH, Thirunavakarasu T, et al. Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. Cancer. 2017; 123(21):4207–14.

14. Parker D, Sloane R, Pieper CF, Hall KS, Kraus VB, Kraus WE, et al. Age-Related Adverse Inflammatory and Metabolic Changes Begin Early in Adulthood. The journals of gerontology Series A, Biological sciences and medical sciences. 2019; 74(3):283–9. https://doi.org/10.1093/gerona/gly121 PMID: 29985987

15. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153(6):1194–217. https://doi.org/10.1016/j.cell.2013.05.039 PMID: 23746838
16. Franceschi C, Campisi J. Chronic inflammation (inflamming) and its potential contribution to age-associated diseases. The journals of gerontology Series A, Biological sciences and medical sciences. 2014; 69 Suppl 1:S4–9.

17. Richter V, Rassoul F, Purschwitz K, Hentschel B, Reuter W, Kuntze T. Circulating vascular cell adhesion molecules VCAM-1, ICAM-1, and E-selectin in dependence on aging. Gerontology. 2003; 49(5):293–300. https://doi.org/10.1159/000071710 PMID: 12920349

18. Kraus WE, Pieper CF, Huffman KM, Thompson DK, Kraus VB, Morey MC, et al. Association of Plasma Small-Molecule Intermediate Metabolites With Age and Body Mass Index Across Six Diverse Study Populations. The journals of gerontology Series A, Biological sciences and medical sciences. 2016; 71(11):1507–13. https://doi.org/10.1093/gerona/glw031 PMID: 26984390

19. Huffman KM, Koves TR, Hubal MJ, Abouassi H, Beri N, Bateman LA, et al. Metabolite signatures of exercise training in human skeletal muscle relate to mitochondrial remodelling and cardiometabolic fitness. Diabetologia. 2014; 57(11):2282–95. https://doi.org/10.1007/s00125-014-3343-4 PMID: 25091629

20. Lum H, Sloane R, Huffman KM, Kraus VB, Thompson DK, Kraus WE, et al. Plasma acylcarnitines are associated with physical performance in elderly men. The journals of gerontology Series A, Biological sciences and medical sciences. 2011; 66(5):548–53. https://doi.org/10.1093/gerona/glr006 PMID: 21367961

21. Cherry JD, Stein TD, Tripodis Y, Alvarez VE, Huber BR, Au R, et al. CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease. PLoS one. 2017; 12(9):e0185541. https://doi.org/10.1371/journal.pone.0185541 PMID: 28965005

22. Eid RS, Chalton JA, Lieblich SE, Bodnar TS, Weinberg J, Galea LAM. Early and late effects of maternal experience on hippocampal neurogenesis, microglia, and the circulating cytokine milieu. Neurobiology of aging. 2018; 78:1–17. https://doi.org/10.1016/j.neurobiaging.2018.01.021 PMID: 30859663

23. Cutler A, Oliveira J, Ferreira R, Challis B, Walker N, Caddy S, et al. Capturing the systemic immune signature of chronic inflammation (inflamming) and its potential contribution to age-associated diseases. The journals of gerontology Series A, Biological sciences and medical sciences. 2016; 71(11):1507–13. https://doi.org/10.1093/gerona/glw031 PMID: 26984390

24. Ferrara JLM, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011; 118(25):6702–8. https://doi.org/10.1182/blood-2011-08-375006 PMID: 21979939

25. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. The New England journal of medicine. 2013; 369(6):529–39. https://doi.org/10.1056/NEJMoa1213299 PMID: 23924003

26. Paczesny S. Acute Graft-Versus-Host Disease Prognosis: Are Biomarkers Ready for Premptive Clinical Trials? Clin Chem. 2017; 63(10):1561–3. https://doi.org/10.1373/clinchem.2017.272872 PMID: 28687636

27. Hartwell MJ, Ozbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI insight. 2017; 2(3):e98798. https://doi.org/10.1172/jci.insight.98798 PMID: 28194439

28. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. Blood. 2018. https://doi.org/10.1182/blood-2018-01-229577 PMID: 29545329

29. Lounder DT, Khandelwal P, Gloude NJ, Dandoy CE, Jodele S, Medvedovic M, et al. Interleukin-22 levels are increased in gastrointestinal graft versus host disease in children. Haematologica. 2018. https://doi.org/10.3324/haematol.2017.174771 PMID: 29773594

30. Adom D, Rowan C, Adeniyi T, Yang J, Paczesny S, Biomarkers for Allogeneic HCT Outcomes. Frontiers in immunology. 2020; 11:673. https://doi.org/10.3389/fimmu.2020.00673 PMID: 32373125

31. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nature medicine. 2004; 10(3):268–74. https://doi.org/10.1038/nm995 PMID: 14770177

32. Ferrara CT, Wang P, Neto EC, Stevens RD, Bain JR, Wenner BR, et al. Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet. 2008; 4(3):e1000034. https://doi.org/10.1371/journal.pgen.1000034 PMID: 18369453

33. McHugh ML. The chi-square test of independence. Biochemica medica. 2013; 23(2):143–9. https://doi.org/10.1161/bm.2013.018 PMID: 23894869

34. Whitley E, Ball J. Statistics review 6: Nonparametric methods. Critical care (London, England). 2002; 6(6):509–13. https://doi.org/10.1186/cc1820 PMID: 12493072

35. Storey JD. A direct approach to false discovery rates. J Roy Stat Soc B. 2002; 64:479–98.
36. Storey JD. False Discovery Rate. In: Lovric M, editor. International Encyclopedia of Statistical Science. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 504–8.
37. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012, 2014.
38. Therneau TM. A Package for Survival Analysis in S. 2015.
39. Xie Y. Dynamic Documents with R and knitr.: Chapman and Hall/CRC; 2015.
40. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 2017; 23(2):211–34. https://doi.org/10.1016/j.bbmt.2016.09.023 PMID: 27713092
41. Sociè G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014; 124(3):374–84. https://doi.org/10.1182/blood-2014-01-514752 PMID: 24914139
42. Shah SH, Sun J-L, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline metabolic profiles predict cardiovascular events in patients at risk for coronary artery disease. American Heart Journal. 2012; 163(5):844–50.e1. https://doi.org/10.1016/j.ahj.2012.02.005 PMID: 22607863
43. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011; 10(3):319–29. https://doi.org/10.1016/j.arr.2010.11.002 PMID: 1453878
44. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. European Journal of Immunology. 1993; 23(9):2375–8. https://doi.org/10.1002/eji.1830230950 PMID: 8370415
45. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009; 113(2):273. https://doi.org/10.1182/blood-2008-07-167098 PMID: 19832652
46. Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD. Int J Hematol. 2011; 93(5):571–7. https://doi.org/10.1007/s12185-011-0803-1 PMID: 21384095
47. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology. 2005; 6(11):1133–41. https://doi.org/10.1038/nri1261 PMID: 16200068
48. Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences. 2019; 20(14).
49. Pidala J, Perez L, Beato F, Anasetti C. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD. Bone Marrow Transplantation. 2012; 47(5):747–8. https://doi.org/10.1038/bmt.2011.172 PMID: 21874061
50. Snyder KJ, Choe HK, Gao Y, Sell NE, Brauneret KM, Zitzer NC, et al. Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. Frontiers in Oncology. 2021; 11:760789. https://doi.org/10.3389/fonc.2021.760789 PMID: 34722316
51. Jordan WJ, Brookes PA, Szydlo RM, Goldman JM, Lechler RI, Ritter MA. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood. 2004; 103(2):717–24. https://doi.org/10.1182/blood-2003-01-0192 PMID: 14512310
52. Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S, et al. The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma. Frontiers in Pharmacology. 2018; 10(1387). https://doi.org/10.3389/fphar.2019.01387 PMID: 31866859
53. Gupta P, Jiang ZK, Yang B, Manzuk L, Rosfjord E, Yao J, et al. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model. MAbs. 2021; 13(1):1958662. https://doi.org/10.1080/19420662.2021.1958662 PMID: 34347577
54. Chang Y, Xu L, An H, Fu Q, Chen L, Lin Z, et al. Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma. Int J Clin Exp Pathol. 2015; 8(2):1594–603. PMID: 25973044
55. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Frontiers in Immunology. 2018; 9:754.
56. Sack GH Jr. Serum amyloid A—a review. Mol Med. 2018; 24(1):46. https://doi.org/10.1186/s10020-018-0047-0 PMID: 30165816
58. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nature immunology. 2010; 11(11):1039–46. https://doi.org/10.1038/ni.1942 PMID: 20890286

59. Knebel FH, Uno M, Galatro TF, Bellé LP, Oba-Shinjo SM, Marie SKN, et al. Serum amyloid A1 is upregulated in human glioblastoma. Journal of neuro-oncology. 2017; 132(3):383–91. https://doi.org/10.1007/s11060-017-2386-z PMID: 28283801

60. Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. North American journal of medical sciences. 2014; 6(10):491–9. https://doi.org/10.4103/1947-2714.143278 PMID: 25489560

61. Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. Journal of pharmacy & bioallied sciences. 2011; 3(1):118–27. https://doi.org/10.4103/0975-7406.76489 PMID: 21430962

62. Song MK, Chung JS, Seol YM, Kwon BR, Shin HJ, Choi YJ, et al. Influence of lactate dehydrogenase and cyclosporine A level on the incidence of acute graft-versus-host disease after allogeneic stem cell transplantation. J Korean Med Sci. 2009; 24(4):555–60. https://doi.org/10.3346/jkms.2009.24.4.555 PMID: 19654932

63. Novitzky N, Thomas V, du Toit C, McDonald A. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2011; 17(6):875–84.

64. Brooks GA. The Science and Translation of Lactate Shuttle Theory. Cell Metab. 2018; 27(4):757–85. https://doi.org/10.1016/j.cmet.2018.03.008 PMID: 29617642

65. Assmann JC, Fartinger DE, Saito K, Maglakelidze N, Oliver BU, Warrick KA, et al. Glycolytic metabolism of pathogenic T cells enables early detection of GvHD by 13C-MRI. Blood. 2020.

66. Kasakin MF, Rogachev AD, Predtechenskaya EV, Zaigraev VJ, Koval VV, Pokrovsky AG. Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls. Multiple sclerosis international. 2020; 2020:9010937. https://doi.org/10.1155/2020/9010937 PMID: 32733709

67. McCoin CS, Knotts TA, Adams SH. Acylcarnitines—old actors auditioning for new roles in metabolic physiology. Nature reviews Endocrinology. 2015; 11(10):617–25. https://doi.org/10.1038/nrendo.2015.129 PMID: 26303601

68. Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, et al. Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation. 2016; 133(21):2038–49. https://doi.org/10.1161/CIRCULATIONAHA.115.020226 PMID: 27059949

69. Hunter WG, Kelly JP, McGarrah RW 3rd, Khouri MG, Craig D, Haynes C, et al. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. Journal of the American Heart Association. 2016; 5(8). https://doi.org/10.1161/JAHA.115.003196 PMID: 27473038

70. Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circulation Cardiovascular genetics. 2010; 3(2):207–14. https://doi.org/10.1161/CIRCGENETICS.109.852814 PMID: 20173117

71. Rutkowsky JM, Knotta TA, Ono-Moore KD, McCoin CS, Huang S, Schneider D, et al. Acylcarnitines activate proinflammatory signaling pathways. Am J Physiol Endocrinol Metab. 2014; 306(12):E1378–87. https://doi.org/10.1152/ajpendo.00656.2013 PMID: 24760988

72. Li S, Gao D, Jiang Y. Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites. 2019; 9(2). https://doi.org/10.3390/metabo9020036 PMID: 30795537

73. Nguyen DC, Gairinalla S, Xiao H, Kyu S, Albizu A, Galipeau J, et al. Factors of the bone marrow micro niche that support human plasma cell survival and immunoglobulin secretion. Nature communications. 2018; 9(1):3696. https://doi.org/10.1038/s41467-018-05853-7 PMID: 30209264

74. Jarrell ZR, Smith MR, Hu X, Orr M, Liu KH, Quyyumi AA, et al. Plasma acylcarnitine levels increase with healthy aging. Aging (Albany NY). 2020; 12(13):13555–70. https://doi.org/10.18632/aging.103462 PMID: 32554854